- AirFit N20 Classic features an all-new adaptive frame with forehead support and the same InfinitySeal cushion as AirFit N20 for optimal fit
LYON, France, Oct. 25, 2017 /PRNewswire/ -- ResMed (NYSE: RMD) today announced the European release of its AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment, to give patients more choices for a stable mask seal and a comfortable night's sleep.
The AirFit N20 Classic features:
- Forehead support that is both clear and slim to maximize comfort and visual freedom.
- The same InfinitySeal silicone mask cushion as the AirFit N20, released last year, which fit 99.4 percent of patients in an international study.1
- An adaptive frame that follows patients' movement while they sleep to maintain an effective seal, much like the AirFit N20.
"Now there are two ways for healthcare providers to offer one great nasal cushion for effective PAP therapy," said Vincent Sauvé, marketing vice president of ResMed's sleep business. "Clinicians can easily switch an AirFit N20 wearer between two frames, while keeping the same cushion, to determine which one will best help them stay on therapy and sleep better."
The AirFit N20 Classic is available now in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Greece, Italy, the Netherlands, Portugal, Romania, Russia, Spain, Sweden, and Turkey.
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries. ResMed.com | Facebook | Twitter | LinkedIn
1 ResMed AirFit N20 internal global fitting study of 159 existing ResMed patients, conducted 11 Dec 2015.
SOURCE ResMed Inc.